These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32653044)

  • 41. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
    Stamp LK; Turner R; Khalilova IS; Zhang M; Drake J; Forbes LV; Kettle AJ
    Rheumatology (Oxford); 2014 Nov; 53(11):1958-65. PubMed ID: 24899662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
    George M; Pullman-Mooar S; Hussain F; Schumacher HR
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2020 American College of Rheumatology Guideline for the Management of Gout.
    FitzGerald JD; Dalbeth N; Mikuls T; Brignardello-Petersen R; Guyatt G; Abeles AM; Gelber AC; Harrold LR; Khanna D; King C; Levy G; Libbey C; Mount D; Pillinger MH; Rosenthal A; Singh JA; Sims JE; Smith BJ; Wenger NS; Bae SS; Danve A; Khanna PP; Kim SC; Lenert A; Poon S; Qasim A; Sehra ST; Sharma TSK; Toprover M; Turgunbaev M; Zeng L; Zhang MA; Turner AS; Neogi T
    Arthritis Rheumatol; 2020 Jun; 72(6):879-895. PubMed ID: 32390306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
    Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
    Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
    Yu KH
    Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):69-75. PubMed ID: 19075968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
    Bruce SP
    Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
    Ye P; Yang S; Zhang W; Lv Q; Cheng Q; Mei M; Luo T; Liu L; Chen S; Li Q
    Clin Ther; 2013 Feb; 35(2):180-9. PubMed ID: 23332451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout.
    Kim SC; Schmidt BM; Franklin JM; Liu J; Solomon DH; Schneeweiss S
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2008-14. PubMed ID: 23861232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
    Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.
    Ellmann H; Bayat S; Araujo E; Manger B; Kleyer A; Cavallaro A; Lell M; Schenker H; Simon D; Tascilar K; Baraf HSB; Schett G; Rech J
    Arthritis Rheumatol; 2020 Jan; 72(1):150-156. PubMed ID: 31353871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Something Old, Something New: the ACR Gout Treatment Guideline and Its Evolution from 2012 to 2020.
    Cohen RE; Pillinger MH; Toprover M
    Curr Rheumatol Rep; 2020 Nov; 23(1):4. PubMed ID: 33245444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Gout].
    Tausche AK
    Internist (Berl); 2021 May; 62(5):513-525. PubMed ID: 33721041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
    Lin YJ; Lin SY; Lin CH; Wang ST; Chang SS
    Clin Rheumatol; 2020 May; 39(5):1633-1648. PubMed ID: 31965378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
    Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
    Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
    Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
    Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.